<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737239</url>
  </required_header>
  <id_info>
    <org_study_id>14552</org_study_id>
    <nct_id>NCT04737239</nct_id>
  </id_info>
  <brief_title>Corticosteroid Injection Effectiveness in Carpel Tunnel Patients With Negative or Mild EMG Studies</brief_title>
  <official_title>Corticosteroid Injection Effectiveness in Carpel Tunnel Patients With Negative or Mild EMG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carpal Tunnel Syndrome (CTS) is the most common nerve entrapment syndrome worldwide. There&#xD;
      are currently no studies examining the effectiveness of corticosteroid injections in patients&#xD;
      with normal (negative) EMG studies. The purpose of this study is to gain a better&#xD;
      understanding of the duration of symptom improvement post corticosteroid injection in&#xD;
      patients with negative or mild EMG studies. The Boston Carpal Tunnel Questionnaire will be&#xD;
      given to patients undergoing corticosteroid injections for the treatment of carpal tunnel&#xD;
      syndrome to assess their response to the injection. Investigators will collect data&#xD;
      retrospectively. The Boston Carpal Tunnel Questionnaire (BCTQ) is administered as per&#xD;
      standard protocol to all patients with CTS who have a negative or mild EMG study. The BCTQ&#xD;
      assesses the patient's self-reported symptom severity and functional status. Investigators&#xD;
      will analyze this data with respect to demographics as well as numbness in the median n.&#xD;
      distribution, nocturnal numbness, weakness/atrophy of the thenar musculature, Tinel's sign,&#xD;
      Phalen's test, loss of 2-point discrimination, Quick-Dash score, and grip strength score.&#xD;
&#xD;
      The primary outcome will be the Boston Carpal Tunnel Questionnaire outcome score under the&#xD;
      different EMG conditions.The secondary outcomes will be numbness in the median n.&#xD;
      distribution, nocturnal numbness, weakness/atrophy of the thenar musculature, Tinel's sign,&#xD;
      Phalen's test, loss of 2-point discrimination, QuickDash score, and grip strength score. Both&#xD;
      outcomes will be examined in patients with negative or mild EMG readings. This information&#xD;
      will allow orthopedic physicians to gain a better understanding of the duration of symptom&#xD;
      improvement post-corticosteroid injection, allowing them to fine tune their treatment plans&#xD;
      for CTS patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">December 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Boston Carpel Tunnel Questionnaire</measure>
    <time_frame>Dec 23 2020-Dec 22 2021</time_frame>
    <description>Scaled 1-5, higher scores indicate worse outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with numbness in the median n. distribution</measure>
    <time_frame>Dec 23 2020-Dec 22 2021</time_frame>
    <description>Positive test includes numbness in parts of palm, thumb, second and third finger, assessed by physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with weakness/atrophy of the thenar musculature</measure>
    <time_frame>Dec 23 2020-Dec 22 2021</time_frame>
    <description>Positive test includes weakness in grip or holding objects as described by participant, assessed by physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with positive Tinel's Sign</measure>
    <time_frame>Dec 23 2020-Dec 22 2021</time_frame>
    <description>Positive sign includes 'pins and needles' in parts of palm, thumb, second and third finger upon percussion of median nerve, assessed by physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with positive Phalen's Test</measure>
    <time_frame>Dec 23 2020-Dec 22 2021</time_frame>
    <description>Positive test includes pain in parts of palm, thumb, second and third finger associated with compression of the median nerve, assessed by physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-point discrimination Test</measure>
    <time_frame>Dec 23 2020-Dec 22 2021</time_frame>
    <description>Scaled 2-8mm, higher scores indicate worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QuickDash score</measure>
    <time_frame>Dec 23 2020-Dec 22 2021</time_frame>
    <description>Scaled 1-100, higher scores indicate worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip Strength score</measure>
    <time_frame>Dec 23 2020-Dec 22 2021</time_frame>
    <description>Scored in pounds(lbs), higher scores indicate better outcomes</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Carpal Tunnel Syndrome</condition>
  <arm_group>
    <arm_group_label>Patient with CTS/Mild EMG</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with CTS/Negative EMG</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Corticosteroid injections for CTS treatment</intervention_name>
    <description>Treatment of carpel tunnel syndrome with corticosteroid injections for EMG mild and EMG negative patients</description>
    <arm_group_label>Patient with CTS/Mild EMG</arm_group_label>
    <arm_group_label>Patient with CTS/Negative EMG</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients clinically diagnosed with CTS, have a negative or mild EMG study, and receive a&#xD;
        corticosteroid injection at Henry Ford Health System Orthopedics.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who speak English&#xD;
&#xD;
          -  Patients who are 18 years or older&#xD;
&#xD;
          -  Patients who are clinically diagnosed with CTS&#xD;
&#xD;
          -  Patients who have a negative or mild EMG study&#xD;
&#xD;
          -  Patients who receive a corticosteroid injection after obtaining a negative or mild EMG&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not speak English&#xD;
&#xD;
          -  Patients who are younger than 18 years of age&#xD;
&#xD;
          -  Patients who have experienced previous trauma to the wrist&#xD;
&#xD;
          -  Patients who have had previous treatment for CTS including but not limited to&#xD;
             corticosteroid injection or surgery&#xD;
&#xD;
          -  Patients with a moderate or severe EMG study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth A Washnock-Schmid, B.S.</last_name>
    <phone>8103474715</phone>
    <email>gn3092@wayne.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aaron R Prater, M.S.</last_name>
    <phone>2692752828</phone>
    <email>aprater1@hfhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles S Day, M.D., M.B.A.</last_name>
      <phone>313-916-5846</phone>
      <email>cday9@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth A Washnock-Schmid, B.S.</last_name>
      <phone>8103474714</phone>
      <email>gn3092@wayne.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Charles S Day, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Padua L, Coraci D, Erra C, Pazzaglia C, Paolasso I, Loreti C, Caliandro P, Hobson-Webb LD. Carpal tunnel syndrome: clinical features, diagnosis, and management. Lancet Neurol. 2016 Nov;15(12):1273-1284. doi: 10.1016/S1474-4422(16)30231-9. Epub 2016 Oct 11. Review.</citation>
    <PMID>27751557</PMID>
  </reference>
  <reference>
    <citation>Graham B, Regehr G, Naglie G, Wright JG. Development and validation of diagnostic criteria for carpal tunnel syndrome. J Hand Surg Am. 2006 Jul-Aug;31(6):919-24.</citation>
    <PMID>16886290</PMID>
  </reference>
  <reference>
    <citation>Visser LH, Ngo Q, Groeneweg SJ, Brekelmans G. Long term effect of local corticosteroid injection for carpal tunnel syndrome: a relation with electrodiagnostic severity. Clin Neurophysiol. 2012 Apr;123(4):838-41. doi: 10.1016/j.clinph.2011.08.022. Epub 2011 Oct 1.</citation>
    <PMID>21962473</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Charles S Day</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>corticosteroid injection</keyword>
  <keyword>electromyography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

